154 related articles for article (PubMed ID: 17332298)
1. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b.
Wang W; Edington HD; Rao UN; Jukic DM; Land SR; Ferrone S; Kirkwood JM
Clin Cancer Res; 2007 Mar; 13(5):1523-31. PubMed ID: 17332298
[TBL] [Abstract][Full Text] [Related]
2. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.
Wang W; Edington HD; Rao UN; Jukic DM; Wang H; Shipe-Spotloe JM; Kirkwood JM
J Invest Dermatol; 2008 Aug; 128(8):1997-2002. PubMed ID: 18305569
[TBL] [Abstract][Full Text] [Related]
3. Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.
Wang W; Edington HD; Jukic DM; Rao UN; Land SR; Kirkwood JM
Cancer Immunol Immunother; 2008 Sep; 57(9):1315-21. PubMed ID: 18386001
[TBL] [Abstract][Full Text] [Related]
4. Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17.
Wang W; Edington HD; Rao UN; Jukic DM; Radfar A; Wang H; Kirkwood JM
Clin Cancer Res; 2008 Dec; 14(24):8314-20. PubMed ID: 19088050
[TBL] [Abstract][Full Text] [Related]
5. Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.
Heise R; Amann PM; Ensslen S; Marquardt Y; Czaja K; Joussen S; Beer D; Abele R; Plewnia G; Tampé R; Merk HF; Hermanns HM; Baron JM
PLoS One; 2016; 11(1):e0146325. PubMed ID: 26735690
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
Kirkwood JM; Richards T; Zarour HM; Sosman J; Ernstoff M; Whiteside TL; Ibrahim J; Blum R; Wieand S; Mascari R
Cancer; 2002 Sep; 95(5):1101-12. PubMed ID: 12209697
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.
Leibowitz MS; Andrade Filho PA; Ferrone S; Ferris RL
Cancer Immunol Immunother; 2011 Apr; 60(4):525-35. PubMed ID: 21207025
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
Moschos SJ; Edington HD; Land SR; Rao UN; Jukic D; Shipe-Spotloe J; Kirkwood JM
J Clin Oncol; 2006 Jul; 24(19):3164-71. PubMed ID: 16809739
[TBL] [Abstract][Full Text] [Related]
9. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
[TBL] [Abstract][Full Text] [Related]
10. Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility.
Aue A; Szelinski F; Weißenberg SY; Wiedemann A; Rose T; Lino AC; Dörner T
Rheumatology (Oxford); 2020 Nov; 59(11):3435-3442. PubMed ID: 32357246
[TBL] [Abstract][Full Text] [Related]
11. STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.
Machiraju D; Moll I; Gebhardt C; Sucker A; Buder-Bakhaya K; Schadendorf D; Hassel JC
Melanoma Res; 2018 Jun; 28(3):204-210. PubMed ID: 29485532
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein.
Humpoliková-Adámková L; Kovařík J; Dušek L; Lauerová L; Boudný V; Fait V; Fojtová M; Krejčí E; Kovařík A
Eur J Cancer; 2009 May; 45(7):1315-1323. PubMed ID: 19232485
[TBL] [Abstract][Full Text] [Related]
13. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients.
Simons DL; Lee G; Kirkwood JM; Lee PP
J Transl Med; 2011 May; 9():52. PubMed ID: 21545749
[TBL] [Abstract][Full Text] [Related]
14. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
Lesinski GB; Trefry J; Brasdovich M; Kondadasula SV; Sackey K; Zimmerer JM; Chaudhury AR; Yu L; Zhang X; Crespin TR; Walker MJ; Carson WE
Clin Cancer Res; 2007 Sep; 13(17):5010-9. PubMed ID: 17785551
[TBL] [Abstract][Full Text] [Related]
15. IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2.
Zimmerer JM; Lehman AM; Ruppert AS; Noble CW; Olencki T; Walker MJ; Kendra K; Carson WE
Clin Cancer Res; 2008 Mar; 14(5):1438-45. PubMed ID: 18316567
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.
Wu ZS; Cheng XW; Wang XN; Song NJ
Melanoma Res; 2011 Dec; 21(6):483-90. PubMed ID: 21876460
[TBL] [Abstract][Full Text] [Related]
17. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
Lesinski GB; Valentino D; Hade EM; Jones S; Magro C; Chaudhury AR; Walker MJ; Carson WE
Cancer Immunol Immunother; 2005 Sep; 54(9):815-25. PubMed ID: 15668815
[TBL] [Abstract][Full Text] [Related]
18. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
Mozzillo N; Ascierto P
Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment.
Smith AP; Kirkwood JM; Edington HD; Jukic DM; Farkas DL; Becker D
Mol Imaging; 2003 Jan; 2(1):65-73. PubMed ID: 12926238
[TBL] [Abstract][Full Text] [Related]
20. Lack of STAT 1 phosphorylation at TYR 701 by IFNgamma correlates with disease outcome in melanoma patients.
Boudny V; Dusek L; Adámková L; Chumchalová J; Kocak I; Fait V; Lauerová L; Krejcí E; Kovarík J
Neoplasma; 2005; 52(4):330-7. PubMed ID: 16059651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
